Last reviewed · How we verify
Botox 100 UNT Injection
Botox 100 UNT Injection is a Botulinum toxin type A Small molecule drug developed by Brigitte Schürch. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox, OnabotulinumtoxinA, onabotulinumtoxinA.
Botox blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botox blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botox 100 UNT Injection |
|---|---|
| Also known as | Botox, OnabotulinumtoxinA, onabotulinumtoxinA |
| Sponsor | Brigitte Schürch |
| Drug class | Botulinum toxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type A binds to and cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at the neuromuscular junction. This prevents muscle contraction in the injected area, producing a temporary paralytic effect that lasts 3–4 months. The effect is reversible as the body gradually regenerates new SNARE complexes.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Glabellar lines and facial wrinkles (cosmetic)
- Spasticity
Common side effects
- Headache
- Injection site pain or bruising
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Diplopia (double vision)
- Neck pain
- Flu-like symptoms
Key clinical trials
- Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial (PHASE4)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
- Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence (PHASE4)
- Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis (PHASE2)
- Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis (PHASE4)
- Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder (PHASE4)
- Xeomin vs Botox for Treatment of Overactive Bladder Syndrome (PHASE2)
- INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox 100 UNT Injection CI brief — competitive landscape report
- Botox 100 UNT Injection updates RSS · CI watch RSS
- Brigitte Schürch portfolio CI
Frequently asked questions about Botox 100 UNT Injection
What is Botox 100 UNT Injection?
How does Botox 100 UNT Injection work?
What is Botox 100 UNT Injection used for?
Who makes Botox 100 UNT Injection?
Is Botox 100 UNT Injection also known as anything else?
What drug class is Botox 100 UNT Injection in?
What development phase is Botox 100 UNT Injection in?
What are the side effects of Botox 100 UNT Injection?
What does Botox 100 UNT Injection target?
Related
- Drug class: All Botulinum toxin type A drugs
- Target: All drugs targeting SNAP-25 (synaptosome-associated protein of 25 kDa)
- Manufacturer: Brigitte Schürch — full pipeline
- Therapeutic area: All drugs in Neurology, Dermatology, Aesthetics
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Strabismus
- Also known as: Botox, OnabotulinumtoxinA, onabotulinumtoxinA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing